secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2023-03-03T23:59:59+00:00
Accession:  0001213900-23-017274
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio FY2022 net loss $27.3M; XPro AD trial under FDA clinical hold
------------------------------------------------------------------------

- Net loss $27.3M vs $30.3M in 2021; R&D expense $17.1M; cash $52.2M at Dec 31, 2022.
- FDA clinical hold on XPro AD trial in US continues; enrollment ongoing in Australia and Canada.
- Phase 2 AD trial topline readout expected 2H 2024; trial consolidated to include MCI patients.
- IND for INKmune in mCRPC to be filed March 2023; Phase I/II trial planned.
- Received ~$6.4M in R&D rebates from Australia and UK; will reinvest in recruitment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390023017274/0001213900-23-017274-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390023017274/ea174635-8k_inmunebio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-017274

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer